1. What is New in Hormone Therapy for Prostate Cancer in 2007?
Bertrand Tombal 
European Urology Supplements 
Volume 7, Issue 6, Pages (April 2008)
DOI: /j.eursup
Copyright © 2008 European Association of Urology Terms and Conditions

2. Fig. 1
Outcomes of the voting on the question: “Which of these indications is not an evidence-based recognised indication of androgen deprivation therapy?”
Answer 1: Immediate treatment of symptomatic patients.
Answer 2: Long life adjuvant treatment of patients with positive lymph nodes at radical prostatectomy.
Answer 3: Short-term (6 mo) adjuvant treatment to external-beam radiation therapy (EBRT) in patients with locally advanced rapidly progressing prostate cancer.
Answer 4: Long-term (3 yr) adjuvant treatment of patients with positive margins and seminal vesicle invasion after radical prostatectomy.
European Urology Supplements 2008 7, DOI: ( /j.eursup )
Copyright © 2008 European Association of Urology Terms and Conditions

3. Fig. 2
Recurrences, overall death, and prostate cancer (PCa)-specific death at a median follow-up of 11.9 yr in patients who received immediate androgen-deprivation therapy (ADT; n=47) versus deferred ADT (n=51) because of positive lymph nodes after radical prostatectomy and pelvic lymphadenectomy [10].
European Urology Supplements 2008 7, DOI: ( /j.eursup )
Copyright © 2008 European Association of Urology Terms and Conditions

4. Fig. 3
General perceptions about the impact of prostate cancer (PCa) on health status after primary androgen-deprivation therapy by means of luteinising hormone-releasing hormone (LHRH) agonists (n=299) or orchidectomy (n=132) [16].
European Urology Supplements 2008 7, DOI: ( /j.eursup )
Copyright © 2008 European Association of Urology Terms and Conditions